about
Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidaseSite-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenyl-butanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitorsBeneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated ratsMolecular dynamics study of prolyl oligopeptidase with inhibitor in binding cavity.Over-expression of a human chromosome 22q11.2 segment including TXNRD2, COMT and ARVCF developmentally affects incentive learning and working memory in miceTranscriptional profiling of C57 and DBA strains of mice in the absence and presence of morphine.Intracerebroventricular antisense knockdown of G alpha i2 results in ciliary stasis and ventricular dilatation in the rat.Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells.Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice.Epistasis between polymorphisms in COMT, ESR1, and GCH1 influences COMT enzyme activity and pain.Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors.Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.Impairing effect of food on ketoconazole absorptionCOMT gene locus: new functional variantsAdvanced brain dopamine transporter imaging in mice using small-animal SPECT/CT.Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumorsGene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's diseaseCatechol-O-methyltransferase (COMT) protein expression and activity after dopaminergic and noradrenergic lesions of the rat brain.High correlation between in vivo [123I]β-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in ratsThe multiple faces of quercetin in neuroprotection.Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors.Effect of genetic modifications in the synaptic dopamine clearance systems on addiction-like behaviour in mice.Association of prolyl oligopeptidase with conventional neurotransmitters in the brain.Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis.Copy number elevation of 22q11.2 genes arrests the developmental maturation of working memory capacity and adult hippocampal neurogenesis.The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.Minocycline protects SH-SY5Y cells from 6-hydroxydopamine by inhibiting both caspase-dependent and -independent programmed cell death.Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo.Pain relief and sputum prostaglandins in adults treated with pethidine, tilidine and indomethacin after tonsillectomy: a double-blind study.Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals.Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons.Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells.Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats.Different viabilities and toxicity types after 6-OHDA and Ara-C exposure evaluated by four assays in five cell lines.A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine.
P50
Q27678385-55F6C341-9761-4E0A-BCE1-98FDA770B8CCQ28249776-9804CA23-3134-4163-A65D-A30057F998E0Q28282683-6840D112-2DE2-4DE6-B03B-E8B723FF6BE2Q28284594-86612E08-A288-4F66-8D3E-DC7FDD0726B3Q30383681-40040F6B-9712-4B34-9770-E90FB0ADC0E0Q30479118-7FBAC956-D4F0-4B66-B2C1-FB877DB411EDQ33279171-49479981-9D02-4012-8B9F-237893183AF0Q33281960-41A31C7B-C043-4FDD-B2F3-1058CBEC7F70Q34022801-7B11AF88-866D-4E15-8DEB-B1EA1DAE81C9Q34125744-193EFD50-3577-4FF0-8D9A-18D4D106FFBEQ34620473-1A098185-AB9A-4476-8257-FA7515414BD5Q34651535-2A25C2F1-2636-4827-8A69-673082751546Q35195523-AF3CEA96-306F-426A-A4D1-A19940DE5C21Q35675648-40DE9BFC-D9A1-42B9-B989-F3DE78241804Q35710613-94CC0055-6CF3-43F0-B4C5-BF0A6DB6DBCAQ36459558-7866E953-C5A8-484D-9D6C-F7487A7AFEB0Q36473292-1691F9B5-15E7-4F3B-8B3B-FF0693152246Q36713101-4CAE7323-4D5F-474C-A4B0-3383BBCBAE38Q36773459-4F7BDB3B-E013-4F4C-8798-A96F629E1B36Q36945574-AC9C8E83-8D86-4E8A-A846-5A85D33F3A4AQ37524001-EE38732C-B18D-4676-8EC7-62C1A11DD4CCQ37693952-DFAE7CAF-2BDA-427C-8B8F-ACE68498F0A1Q37811522-EAEF5404-A9D7-48F5-98B0-B342D3500A93Q37813813-86060E67-4B9D-4710-98F9-67E1E5E18A98Q37827532-F7FB7781-1915-4316-9332-CA29529B2A50Q37941603-03245A91-C587-47E9-92CE-D4EFE7E6A592Q38020683-20E24B02-1496-4979-89BC-49E9E1449890Q38615223-0A8790C8-9278-4757-BE5D-86B61C6A36D8Q39002911-2DEFE84F-072B-4C70-BDB6-89E268214489Q39156437-238657B1-32BC-4F3F-8E99-513F21C10EB7Q39438609-BFE382F3-C65A-48A1-9B05-686DDC01CB3CQ39504953-0293ECF5-4D35-4DA9-AA44-6F0CA4B2BF25Q39571980-2494B137-3384-4906-B639-4CEA384282FBQ39615697-5E2F8E88-4FA3-4A37-8984-2D5A0DF5D782Q39797272-3DB73E2A-49EE-490B-AED1-49F84F84D8FBQ39823929-2C837535-71C6-4862-B008-DAB904FF3810Q39945784-3909F4AD-F9F0-4CE1-90FD-3B508A2E031CQ39965771-63D72EA3-8137-4831-BF12-7C1B7E7BA1BEQ40086369-1897F41D-944F-4FDC-AD49-63CBE69639B9Q40237916-8ABCBFC2-5EC2-4636-A8FC-B514472817E1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pekka T. Männistö
@ast
Pekka T. Männistö
@en
Pekka T. Männistö
@es
Pekka T. Männistö
@nl
Pekka T. Männistö
@sl
type
label
Pekka T. Männistö
@ast
Pekka T. Männistö
@en
Pekka T. Männistö
@es
Pekka T. Männistö
@nl
Pekka T. Männistö
@sl
altLabel
Männistö PT
@en
Pekka Männistö
@en
prefLabel
Pekka T. Männistö
@ast
Pekka T. Männistö
@en
Pekka T. Männistö
@es
Pekka T. Männistö
@nl
Pekka T. Männistö
@sl
P106
P1153
7102064774
P21
P31
P4012
P496
0000-0002-8708-1979